Schivo Michael, Albertson Timothy E, Haczku Angela, Kenyon Nicholas J, Zeki Amir A, Kuhn Brooks T, Louie Samuel, Avdalovic Mark V
Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, California, USA.
Center for Comparative Respiratory Biology and Medicine, Genome and Biomedical Sciences Facility, University of California Davis, Davis, California, USA.
J Investig Med. 2017 Aug;65(6):953-963. doi: 10.1136/jim-2016-000358. Epub 2017 Mar 3.
Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous syndrome that represents a major global health burden. COPD phenotypes have recently emerged based on large cohort studies addressing the need to better characterize the syndrome. Though comprehensive phenotyping is still at an early stage, factors such as ethnicity and radiographic, serum, and exhaled breath biomarkers have shown promise. COPD is also an immunological disease where innate and adaptive immune responses to the environment and tobacco smoke are altered. The frequent overlap between COPD and other systemic diseases, such as cardiovascular disease, has influenced COPD therapy, and treatments for both conditions may lead to improved patient outcomes. Here, we discuss current paradigms that center on improving the definition of COPD, understanding the immunological overlap between COPD and vascular inflammation, and the treatment of COPD-with a focus on comorbid cardiovascular disease.
慢性阻塞性肺疾病(COPD)是一种复杂的异质性综合征,是全球主要的健康负担。基于大型队列研究,COPD表型最近出现,以满足更好地描述该综合征的需求。尽管全面的表型分析仍处于早期阶段,但种族、影像学、血清和呼出气体生物标志物等因素已显示出前景。COPD也是一种免疫性疾病,对环境和烟草烟雾的先天性和适应性免疫反应会发生改变。COPD与其他全身性疾病(如心血管疾病)之间的频繁重叠影响了COPD的治疗,针对这两种疾病的治疗可能会改善患者的预后。在此,我们讨论当前的范式,这些范式围绕改善COPD的定义、理解COPD与血管炎症之间的免疫重叠以及COPD的治疗展开,重点关注合并的心血管疾病。